Publications by authors named "Maurice Overzier"

Duchenne muscular dystrophy is a severe neuromuscular disorder that is caused by mutations in the DMD gene, resulting in a disruption of dystrophin production. Next to dystrophin expression in the muscle, different isoforms of the protein are also expressed in the brain and lack of these isoforms leads to cognitive and behavioral deficits in patients. It remains unclear how the loss of the shorter dystrophin isoform Dp140 affects these processes.

View Article and Find Full Text PDF

In Huntington disease, cellular toxicity is particularly caused by toxic protein fragments generated from the mutant huntingtin (HTT) protein. By modifying the HTT protein, we aim to reduce proteolytic cleavage and ameliorate the consequences of mutant HTT without lowering total HTT levels. To that end, we use an antisense oligonucleotide (AON) that targets HTT pre-mRNA and induces partial skipping of exon 12, which contains the critical caspase-6 cleavage site.

View Article and Find Full Text PDF
Article Synopsis
  • Becker muscular dystrophy (BMD) shows slow progression, highlighting the need for biomarkers to support clinical trials; researchers examined changes in three muscle-enriched biomarkers in BMD patients over four years to evaluate their relation to disease severity and progression.
  • The study involved measuring creatine kinase, creatine/creatinine levels, and myostatin in patient serum while assessing functional performance through various tests, revealing a strong correlation between Cr/Crn and myostatin with functional outcomes, but a weak association with creatine kinase.
  • Outcomes from 34 patients indicated that specific biomarkers could explain up to 75% of the variance in functional performance, although dystrophin levels did not show a correlation with these biomarkers or patient performance
View Article and Find Full Text PDF

While the genetic cause of Huntington disease (HD) is known since 1993, still no cure exists. Therapeutic development would benefit from a method to monitor disease progression and treatment efficacy, ideally using blood biomarkers. Previously, HD-specific signatures were identified in human blood representing signatures in human brain, showing biomarker potential.

View Article and Find Full Text PDF

Objective: To determine the small vessel disease spectrum associated with cysteine-altering variants in community-dwelling individuals by analyzing the clinical and neuroimaging features of UK Biobank participants harboring such variants.

Methods: The exome and genome sequencing datasets of the UK Biobank (n = 50,000) and cohorts of cognitively healthy elderly (n = 751) were queried for cysteine-altering variants. Brain MRIs of individuals harboring such variants were scored according to Standards for Reporting Vascular Changes on Neuroimaging criteria, and clinical information was extracted with ICD-10 codes.

View Article and Find Full Text PDF

This study investigates changes with respect to increasing protein levels in dystrophic nerves of two mdx mouse models of Duchenne muscular dystrophy (DMD). We propose that these nerve changes result from progressive ongoing damage to neuromuscular junctions (NMJs) due to repeated intrinsic bouts of necrosis in dystrophic muscles. We compared sciatic nerves from classic mdx mice aged 13, 15 and 18 months (M), with D2.

View Article and Find Full Text PDF

CADASIL is a vascular protein aggregation disorder caused by cysteine-altering NOTCH3 variants, leading to mid-adult-onset stroke and dementia. Here, we report individuals with a cysteine-altering NOTCH3 variant that induces exon 9 skipping, mimicking therapeutic NOTCH3 cysteine correction. The index came to our attention after a coincidental finding on a commercial screening MRI, revealing white matter hyperintensities.

View Article and Find Full Text PDF
Article Synopsis
  • CADASIL is a disease linked to NOTCH3 that affects small blood vessels in the brain, characterized by GOM deposits in arteries; however, how these deposits form and affect disease progression is not well understood.
  • Researchers studied GOM deposits in genetically modified mice and human patients, discovering that these deposits are dynamic and grow larger and more complex as the mice age, which led to the creation of a new classification system.
  • Despite similarities in GOM stages between mice and humans, the mutant mice didn't develop the most severe GOM seen in patients, highlighting a lack of severe associated brain damage and cognitive deficits, suggesting the need for further research on GOM's role in CADASIL.
View Article and Find Full Text PDF

The C57BL/10ScSn-/J (BL10-) mouse has been the most commonly used model for Duchenne muscular dystrophy (DMD) for decades. Their muscle dysfunction and pathology is, however, less severe than in patients with DMD, which complicates preclinical studies. Recent discoveries indicate that disease severity is exacerbated when muscular dystrophy mouse models are generated on a DBA2/J genetic background.

View Article and Find Full Text PDF

Background: Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder caused by expansion of the polyglutamine repeat in the ataxin-3 protein. Expression of mutant ataxin-3 is known to result in transcriptional dysregulation, which can contribute to the cellular toxicity and neurodegeneration. Since the exact causative mechanisms underlying this process have not been fully elucidated, gene expression analyses in brains of transgenic SCA3 mouse models may provide useful insights.

View Article and Find Full Text PDF

Skeletal muscle fibrosis and impaired muscle regeneration are major contributors to muscle wasting in Duchenne muscular dystrophy (DMD). Muscle growth is negatively regulated by myostatin (MSTN) and activins. Blockage of these pathways may improve muscle quality and function in DMD.

View Article and Find Full Text PDF